



Christopher Arendt, Ph.D.

Head, Oncology
Therapeutic Area Unit

Based at Takeda's Cambridge, Massachusetts, R&D campus, Dr. Arendt is responsible for oversight of Takeda's global Oncology Development portfolio. Since joining Takeda in 2015, Dr. Arendt has helped reshape Takeda's Oncology pipeline with a strong network of global collaborators, emphasizing emerging science leveraging immunological modalities and mechanisms towards curative-intent cancer medicines.

Dr. Arendt is a PhD Immunologist who carried out postdoctoral training with Dan Littman at the New York University Medical Center. Prior to joining Takeda, Dr. Arendt spent more than 13 years at Sanofi, where he led global teams advancing novel immunotherapies for cancers and inflammatory diseases.



ONCOLOGY